Therapy for Stage IV Non‑Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.0
This guideline provides evidence‑based recommendations for treating patients with stage IV non‑small cell lung cancer (NSCLC) without driver alterations.
This ASCO living guideline offers continually updated recommendations based on an ongoing systematic review of randomized controlled trials (RCTs).
Providing evidence‑based recommendations for treating stage IV NSCLC without driver alterations helps clinicians choose optimal therapies and improves patient outcomes.
Evidence level: Számítógépes vagy elméleti. Modellből vagy adatbányászatból származó jel.
Related signals
- Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer
- Ramucirumab plus erlotinib in patients with untreated, EGFR‑mutated, advanced non‑small‑cell lung cancer (RELAY): a randomised, double‑blind, placebo‑controlled, phase 3 trial
- Recent advancements in lung cancer research: a narrative review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
- Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT